Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1137511

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has in place to ensure that every cancer patient who would benefit from radiotherapy is able to access that treatment.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	274632
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>The NHS Long Term Plan reaffirmed the commitment to modernise radiotherapy, as well as making specific commitments to commission the National Health Service new state-of-the-art Proton Beam facilities in London and Manchester. The plan also committed to reforming the specialised commissioning payments for radiotherapy hypofractionation to support further equipment upgrades.</p><p>The Long Term Plan also set out NHS England’s commitment to review the National Tariff, in particular to ensure that appropriate incentives are in place to encourage providers to deliver modern techniques, including hypofractionation, and to upgrade and replace equipment.</p><p>Over the last two years, £130 million has been invested in modernising radiotherapy equipment, with over 80 machines funded for replacement or upgrade across the country since October 2016.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 16/07/2019 14:37:11 answering member 4455 label Biography information for Seema Kennedy
tabling member	4658 label Biography information for Alex Sobel

1122120

registered interest
date	18/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prepare cardiac units for the UK leaving the EU without a deal.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	245973
answer	answer is ministerial correction date of answer 30/04/2019 answer text <p>We have now reached agreement with the European Union on an extension until 31 October 2019 at the latest, with the option to leave earlier as soon as a deal has been ratified. Although Parliament has rejected leaving without a deal multiple times, this remains the legal default at the end of the extension period, unless a deal is passed by Parliament.</p><p>In light of the extension, Departments will make sensible decisions about the timing and pace at which some of this work is progressing, but we will continue to prepare for all exit scenarios. We remain focused on ensuring our smooth and orderly withdrawal from the EU with a deal as soon as possible.</p><p>The Department is considering the impact on our EU exit preparations and we are working closely with our stakeholders to review our position.</p><p>While we never give guarantees, we are confident that, if everyone does what they need to do, the supply of medicines and medical products, including for supplies of clinical trials and investigations, will be uninterrupted in the event we leave the EU without a deal.</p><p>In terms of EU exit preparations for local National Health Service organisations, on 18 April 2019 Professor Keith Willett, EU Exit Strategic Commander at NHS England and NHS Improvement, wrote to clinical commissioning group and trust Chief Executives to update them on the further extension to Article 50, and the actions that now need to be taken locally to continue to prepare for the United Kingdom’s exit from the EU. Further details are available in Professor Willett’s letter that NHS England and NHS Improvement has published online at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/04/20130418-KW-EU-exit-letter-final-.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/04/20130418-KW-EU-exit-letter-final-.pdf</a></p><p>These actions will also apply to cardiac units as they are within trusts.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 30/04/2019 10:04:54 answering member 1585 label Biography information for Stephen Hammond
tabling member	4658 label Biography information for Alex Sobel

1105241

registered interest
date	26/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cerliponase Alfa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to make Cerliponase alfa, marketed as Brineura, available on the NHS for the treatment of ceroid lipofuscinosis type 2.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	237175
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing highly specialised technology (HST) guidance on Brineura (cerliponase alfa) for treating neuronal ceroid lipofuscinosis type 2. Further information can be found at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/indevelopment/gid-hst10008" target="_blank">https://www.nice.org.uk/guidance/indevelopment/gid-hst10008</a></p><p> </p><p>Through its HST programme, NICE makes recommendations on whether very high cost drugs for very small numbers of patients represent an effective use of the National Health Service resources. NHS England is required to fund medicines recommended in NICE’s HST guidance, normally within three months of the publication of final guidance.</p><p> </p><p>In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 15:46:55 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4658 label Biography information for Alex Sobel

1104818

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to secure a deal with Vertex on access for patients to the drug Orkambi on the NHS.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	236525
answer	answer is ministerial correction date of answer 01/04/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines, including Orkambi.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the NHS.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care held a meeting on 11 March with all the parties to discuss how best to reach a deal so that people with cystic fibrosis and their families can benefit as soon as possible. Vertex, NICE and NHS England subsequently met on Thursday 21 March and have agreed to continue discussions.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 01/04/2019 11:40:40 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4658 label Biography information for Alex Sobel

1104821

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Yorkshire and the Humber
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to reduce waiting times (a) for NHS operations and (b) between admission and treatment at A&E in Yorkshire and the Humber.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	236528
answer	answer is ministerial correction date of answer 01/04/2019 answer text <p>Positive work has been delivered within Leeds Teaching Hospitals NHS Trust as well as the wider Leeds health and social care economy. Through this, significant improvements have been seen over the past 12 months, including over the winter period. Over winter, these improvements have included:</p><p>- A significant reduction in the the number of patients waiting longer than 52 weeks for operations;</p><p>- A 10% increase in the number of patients seen within four hours in emergency departments in February, compared to previous year; and</p><p>- Zero 12-hour breaches within emergency departments.</p><p> </p><p>In addition to this, further service improvements made across hospitals in the area over the last 12 months have included modelling to predict surges in demand, extra consultant presence in the emergency department and work to discharge patients earlier in the day.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 01/04/2019 15:25:53 answering member 1585 label Biography information for Stephen Hammond
tabling member	4658 label Biography information for Alex Sobel

1088695

registered interest
date	14/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase (a) patient and (b) clinician awareness of the (i) effect on carbon emissions of inhalers and (ii) range of low carbon inhalers available; and how he plans to measure progress on the increased use of low carbon inhalers in the NHS.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	232644
answer	answer is ministerial correction date of answer 21/03/2019 answer text <p>The Sustainable Development Unit (SDU), a joint NHS England and Public Health England unit, has established a cross sector working group on low carbon inhalers. The group includes representation from a number of patient and clinician groups, as well as cross Government representation.</p><p> </p><p>A cross system approach is now being developed into a system wide implementation plan, with specific actions being delivered by individual members of the group. All actions are supporting progress towards or exceed the NHS Long Term Plan commitment on low carbon inhalers. This will contribute to the overall National Health Service commitment in the Long Term Plan to reduce carbon emissions in line with the UK Climate Change Act.</p><p> </p><p>The SDU is also engaging centrally with systematic data collection and data provision systems for clinicians and local system leaders to help ensure that clinical and strategic decision makers are aware how their local area is performing with regards to achieving the national targets in the Long Term Plan and what options are available for them to further reduce the carbon emissions of local prescribing and inhaler waste management practice.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 232504 question first answered 21/03/2019 17:05:52 answering member 4067 label Biography information for Steve Brine
tabling member	4658 label Biography information for Alex Sobel

1086565

registered interest
date	11/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Eating Disorders: Yorkshire and the Humber
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has in place to ensure that people in Yorkshire of all categories of (a) gender, (b) sexuality, (c) age and (d) ethnicity and background with an eating disorder are able to access treatment and support.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	230869
answer	answer is ministerial correction date of answer 19/03/2019 answer text <p>The Government is committed to ensuring everyone with an eating disorder, regardless of their geographical location has access to timely treatment based on clinical need. NHS England’s ‘Access and Waiting Time Standard for Children and Young People with an Eating Disorder: Commissioning Guide’ sets out guidance on establishing and maintaining eating disorder services.</p><p> </p><p>It states that eating disorder services for young people should follow the overarching principles for service design and development for children’s services required of local transformation plans. This includes meeting legal duties with regard to equality, with an aim to reduce inequality in access and outcomes.</p><p> </p><p>The guidance is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2015/07/cyp-eating-disorders-access-waiting-time-standard-comm-guid.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2015/07/cyp-eating-disorders-access-waiting-time-standard-comm-guid.pdf</a></p><p> </p><p>Every area produces an annual joint agency local transformation plan that sets out how services will improve children and young peoples’ mental health outcomes using the new resources. These plans support local governance and oversight and are included in sustainability and transformation plans for the wider National Health Service and social care system.</p><p> </p><p>The first waiting times have been set up to improve access to eating disorders services for children and young people. By 2020/21, 95% of children with an eating disorder will receive treatment within one week for urgent cases and within four weeks for routine cases. The latest figures indicate that the NHS is on track to meet that standard.</p><p> </p><p>The NHS Long Term Plan commits to “test four-week waiting times for adult and older adult community mental health teams, with selected local areas”. The exact scope and timelines of these pilots are yet to be finalised but we envisage that this will include testing waiting times for adult eating disorder services in those areas in receipt of new funding to expand these services.</p><p> </p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 19/03/2019 17:51:06 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4658 label Biography information for Alex Sobel

1081780

registered interest
date	04/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Plastic Surgery: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to bring forward regulations on who is permitted to administer (a) botox injections and (b) dermal fillers.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	228087
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>The Medicines and Healthcare products Regulatory Agency is responsible for regulating all medicines and medical devices in the United Kingdom.</p><p>Botulinum injections (commonly known under the brand name ‘Botox’) are prescription-only medicines. A prescriber may delegate responsibility for the administration of the medicine, but they retain responsibility for ensuring that the secondary practitioner provides the treatment safely.</p><p>Currently, a dermal filler may be regulated either as a general product, a medicine or a medical device, depending on its composition and intended use. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). Whilst it is outside of the remit of the Regulations to make provisions for who can administer or use medical devices on another person, the Regulations will significantly strengthen the quality assurance and safety of dermal fillers.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 11/03/2019 14:27:19 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4658 label Biography information for Alex Sobel

1056730

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antibiotics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he has taken to secure the supply of antibiotics in the event of the UK without a deal.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	218365
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>We understand that antibiotics are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of antibiotics and other essential medicines for patients is not disrupted.</p><p> </p><p>In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines, including antibiotics, to the UK that come from, or via, the EU/European Economic Area (EEA) asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019. We recognise, however, that certain medicines cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a ‘no deal’ exit.</p><p> </p><p>On 7 December, the Government published updated reasonable worst-case scenario border disruption planning assumptions in the event of a ‘no deal’ EU exit. Medicines and medical products are prioritised in cross-Government planning, and the Department is working with relevant partners across Government and industry to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely into the UK.</p><p> </p><p>Throughout enacting our plans, we have received very good engagement from industry who share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a ‘no deal’ EU exit.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 14/02/2019 12:21:54 answering member 1585 label Biography information for Stephen Hammond
tabling member	4658 label Biography information for Alex Sobel

1054660

registered interest
date	04/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cerliponase Alfa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will hold meetings with families of children with ceroid lipofuscinosis type 2 disease on the availability of Brineura on the NHS.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	216384
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department has no plans currently. The National Institute for Health and Care Excellence is currently developing guidance on Brineura (Cerliponase alfa) for treating neuronal ceroid lipofuscinosis type 2 under the highly specialised technology programme. Further information can be found at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/indevelopment/gid-hst10008" target="_blank">https://www.nice.org.uk/guidance/indevelopment/gid-hst10008</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:49:07 answering member 4067 label Biography information for Steve Brine
tabling member	4658 label Biography information for Alex Sobel